Review of GSK-Pfizer consumer-healthcare deal in Australia kicks off
The plan by GlaxoSmithKline and Pfizer to combine their rival consumer-healthcare businesses will go under Australia’s informal review process starting today, with the country’s antitrust regulator keen on analyzing the importance...To view the full article, register now.
Already a subscriber? Click here to view full article